The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients with TP53-mutated, HER2 Negative Stage IIa – IIIb Breast Cancer Receiving Neoadjuvant Chemotherapy